Upcoming therapeutic options for progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
O9: Mechanisms and Therapeutic Options in Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system associated to myelin loss and neurodegeneration. Clinically patients suffer from diverse symptoms and face the risk to become wheelchair-bound. At the moment MS is incurable, thus there is an unmet need for therapeutic options.
متن کاملTherapeutic options in multiple sclerosis
Neurology® Clinical Practice 2010;75(Suppl 1):S22–S27 Care of the patient with multiple sclerosis (MS) is becoming increasingly complex, with new symptomatic therapies (e.g., dalfampridine), enhanced use of disease-modifying therapies that are potentially both more efficacious and more risky (e.g., natalizumab, rituximab) than “standard” immunomodulators, the advent of oral disease-modifying th...
متن کاملP 57: The Effect of Biotin as a Therapeutic Agent for Progressive Multiple Sclerosis
Multiple sclerosis is an autoimmune disease caused by damage to the myelin of the nerve cells in the spinal cord and brain, MS was classified into 4 types including: Relasping/remitting (RR) primary/progressive (PP), secondary/progressive (SP), progressive/relapsing (PR). PR MS is one of the severe forms of MS that lead to inflammation associated physical, mental and vision dysfunction. Because...
متن کاملMetabolic pathways as possible therapeutic targets for progressive multiple sclerosis
Unlike relapsing remitting multiple sclerosis, there are very few therapeutic options for patients with progressive forms of multiple sclerosis. While immune mechanisms are key participants in the pathogenesis of relapsing remitting multiple sclerosis, the mechanisms underlying the development of progressive multiple sclerosis are less well understood. Putative mechanisms behind progressive mul...
متن کاملTherapeutic options for systemic sclerosis.
Systemic sclerosis is a uncommon connective tissue disorder characterized by vascular damage, immune cell activation and fibrogenesis. Each of these components may respond to different therapies. Therefore, a combination strategy treating all three processes is more likely to control the disease than single agent therapy. Clinical trials have gone a long way towards defining the therapy of scle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hamdan Medical Journal
سال: 2017
ISSN: 2227-2437
DOI: 10.7707/hmj.809